Aura Biosciences Q3 net loss $8.8M; AU-011 data and IPO highlight quarter

Aura Biosciences, Inc.

2022-Q3 EPS reported -$77.93

Net loss $8.8M for Q3 2021 vs $3.6M YoY; R&D expenses $6.4M (up from $2.9M).
Cash $81.8M at Sep 30; IPO raised $86.9M gross in Nov 2021 at $14.00/share.
Final Phase 1b/2 data: 64% tumor control, 71% visual acuity preservation for AU-011 in choroidal melanoma.
Plans to start AU-011 pivotal program H2 2022; Phase 1a in NMIBC expected H2 2022.
Added Antony Mattessich to board and Chris Primiano as CBO in September 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.